Biologic Lyophilization Cake Quality Patents: Leaders & Trends 2026
Biologic Lyophilization Cake Quality Patents: Who Holds the Claims
Concentration is modest. The top 5 assignees hold just 9.7% of all 7,397 records in scope, and the top 10 hold 16.5% — filing rights here are spread far wider than in a typical concentrated pharma niche. Filings ran at 431 in 2017 and reached a peak of 498 in 2019. The 2021-to-2024 window, the most recent span complete enough to compare, shows a -46% move from 451 to 243 records — a real pullback, not a publication-lag artefact, though 2025-2026 figures will still revise upward.
- 1TAKEDA PHARMA CO LTD2.1%
- 2AMGEN INC2.1%
- 3REGENERON PHARMACEUTICALS INC2.0%
- 4MERCK SHARP & DOHME LLC1.8%
- 5GENENTECH INC1.7%
See the full biologic lyophilization cake quality analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents on biologic lyophilization cake quality?
The leading assignee in this dataset holds 156 of the 7,397 records in scope, with the fifth-ranked assignee at 123 and the tenth at 85. Together the top 5 hold 9.7% of all records and the top 10 hold 16.5%, which means no single company dominates the field the way a leader might in a narrower niche. The remaining records are spread across a long tail of smaller filers, including academic and CDMO-affiliated entities not in the ranked leaders.
Is patent filing in this area growing or shrinking?
Filings peaked at 498 records in 2019 and have declined since, with the most recent complete comparison showing a -46% drop from 451 records in 2021 to 243 in 2024. The 2025 and 2026 figures in the raw trend look lower still, but that is expected: publication typically lags filing by around 18 months, so those final years will revise upward as more applications publish. The 2021-to-2024 window is the most reliable recent signal, and it does point to a genuine cooling.
What’s the difference between formulation claims and drying-process claims here?
Formulation claims, largely filed under A61K, cover the biologic’s stabilizers, excipients and buffer chemistry and touch 88.5% of the 7,397 records in this landscape. Drying-process and equipment claims, filed under F26B, cover the freeze-dryer cycle itself — shelf temperature ramps, primary and secondary drying parameters, chamber pressure control — and appear on only 14.5% of records. That gap suggests process-engineering routes to cake-quality improvements carry comparatively less prior art than formulation routes.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Biologic Lyophilization Cake Quality covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.